{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:53:22Z","timestamp":1781639602564,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07817-2","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T01:42:14Z","timestamp":1772415734000},"page":"4873-4882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["[177Lu]Lu-PSMA radioligand therapy in younger prostate cancer patients: A matched-pair analysis between patients\u2009\u2264\u200965 and \u2265\u200970 years old"],"prefix":"10.1007","volume":"53","author":[{"given":"Johannes","family":"Hornfeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Dahlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie C.","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz J.","family":"Gildehaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Delker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina-Sophie","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Bundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias J.","family":"Zacherl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-9338","authenticated-orcid":false,"given":"Liam","family":"Widjaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"12","key":"7817_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic Castration-Resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"8","key":"7817_CR2","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.2967\/jnumed.122.265259","volume":"64","author":"R Tauber","year":"2023","unstructured":"Tauber R, Knorr K, Retz M, et al. Safety and efficacy of [(177)Lu]-PSMA-I&T radioligand therapy in octogenarians with metastatic Castration-Resistant prostate cancer: report on 80 patients over the age of 80 years. J Nucl Med. 2023;64(8):1244\u201351.","journal-title":"J Nucl Med"},{"issue":"21","key":"7817_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17213515","volume":"17","author":"N Schweigert","year":"2025","unstructured":"Schweigert N, Strewinsky N, Kohler D, et al. Age-related outcomes of [(177)Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a retrospective analysis. Cancers (Basel). 2025;17(21):3515.","journal-title":"Cancers (Basel)"},{"issue":"10276","key":"7817_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. [(177)Lu]Lu-PSMA-617 versus Cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804.","journal-title":"Lancet"},{"issue":"10459","key":"7817_CR5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227\u201339.","journal-title":"Lancet"},{"key":"7817_CR6","unstructured":"Novartis Pluvicto\u2122 demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer: Novartis. 2025 [Available from: https:\/\/www.novartis.com\/news\/media-releases\/novartis-pluvictotm-demonstrates-statistically-significant-and-clinically-meaningful-rpfs-benefit-patients-psma-positive-metastatic-hormone-sensitive-prostate-cancer"},{"key":"7817_CR7","unstructured":"Food and Drug Aministration. FDA expands Pluvicto\u2019s metastatic castration-resistant prostate cancer indication; 28.03.2025. Available under: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication. Last accessed 17.06.2025."},{"issue":"12","key":"7817_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122938","volume":"13","author":"L Widjaja","year":"2021","unstructured":"Widjaja L, Werner RA, Ross TL, Bengel FM, Derlin T. PSMA expression predicts early biochemical response in patients with metastatic castration-resistant prostate cancer under (177)Lu-PSMA-617 radioligand therapy. Cancers (Basel). 2021;13(12):2938.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"7817_CR9","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","volume":"50","author":"PE Hartrampf","year":"2023","unstructured":"Hartrampf PE, Huttmann T, Seitz AK, et al. SUV(mean) on baseline [(18)F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [(177)Lu]Lu-PSMA I&T. Eur J Nucl Med Mol Imaging. 2023;50(11):3465\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7817_CR10","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1007\/s00259-021-05237-y","volume":"48","author":"R Manafi-Farid","year":"2021","unstructured":"Manafi-Farid R, Harsini S, Saidi B, et al. Factors predicting biochemical response and survival benefits following radioligand therapy with [(177)Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. Eur J Nucl Med Mol Imaging. 2021;48(12):4028\u201341.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7817_CR11","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Weinzierl FX, Buck AK, et al. Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49(9):3269\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7817_CR12","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.1007\/s00259-025-07319-7","volume":"52","author":"SC Kunte","year":"2025","unstructured":"Kunte SC, Delker A, Holzgreve A, et al. [(99m)Tc]Tc-antigranulocyte scintigraphy for prediction of bone marrow reserve prior to radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52(12):4446\u201355.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7817_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-025-01211-z","volume":"15","author":"GT Sheikh","year":"2025","unstructured":"Sheikh GT, Delker A, Zacherl MJ, et al. RECIP 1.0\u2009+\u2009PSA for response assessment in mCRPC patients treated with (225)Ac \/ (177)Lu PSMA combination therapy. EJNMMI Res. 2025;15(1):19.","journal-title":"EJNMMI Res"},{"key":"7817_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10050946","author":"LM Unterrainer","year":"2022","unstructured":"Unterrainer LM, Beyer L, Zacherl MJ, et al. Total tumor volume on (18)F-PSMA-1007 PET as additional imaging biomarker in mCRPC patients undergoing PSMA-targeted alpha therapy with (225)Ac-PSMA-I&T. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10050946.","journal-title":"Biomedicines"},{"issue":"7","key":"7817_CR15","first-page":"1054","volume":"66","author":"LM Unterrainer","year":"2025","unstructured":"Unterrainer LM, De Leiris N, Unterrainer M, et al. Evidence-Based clinical protocols to monitor efficacy of [(177)Lu]Lu-PSMA radiopharmaceutical therapy in metastatic Castration-Resistant prostate cancer using Real-World data. J Nucl Med. 2025;66(7):1054\u201360.","journal-title":"J Nucl Med"},{"key":"7817_CR16","doi-asserted-by":"crossref","unstructured":"Widjaja L, Hornfeck J, Siegmund SC et al. Refining the clinical utility of [(177)Lu]Lu\/[(225)Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2025.","DOI":"10.1007\/s00259-025-07632-1"},{"issue":"5","key":"7817_CR17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.120.251017","volume":"62","author":"MJ Zacherl","year":"2021","unstructured":"Zacherl MJ, Gildehaus FJ, Mittlmeier L, et al. First clinical results for PSMA-Targeted alpha-Therapy using (225)Ac-PSMA-I&T in Advanced-mCRPC patients. J Nucl Med. 2021;62(5):669\u201374.","journal-title":"J Nucl Med"},{"issue":"9","key":"7817_CR18","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, et al. Joint EANM\/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50(9):2830\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7817_CR19","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402\u201318.","journal-title":"J Clin Oncol"},{"key":"7817_CR20","unstructured":"SERVICES USDOHAH. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 2017 [Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"7817_CR21","doi-asserted-by":"crossref","unstructured":"Ahmadzadehfar H, Rahbar K, Baum RP. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48(1):113\u201322.","DOI":"10.1007\/s00259-020-04797-9"},{"issue":"17","key":"7817_CR22","doi-asserted-by":"publisher","first-page":"7812","DOI":"10.7150\/thno.47251","volume":"10","author":"R Seifert","year":"2020","unstructured":"Seifert R, Seitzer K, Herrmann K, et al. Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving (177)Lu-PSMA-617 Radioligand Therapy. Theranostics. 2020;10(17):7812\u201320.","journal-title":"Theranostics"},{"issue":"1","key":"7817_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/pros.24250","volume":"82","author":"L Widjaja","year":"2022","unstructured":"Widjaja L, Derlin T, Ross TL, Bengel FM, Werner RA. Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy. Prostate. 2022;82(1):86\u201396.","journal-title":"Prostate"},{"issue":"12","key":"7817_CR24","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1007\/s00259-021-05412-1","volume":"48","author":"L Widjaja","year":"2021","unstructured":"Widjaja L, Werner RA, Ross TL, Bengel FM, Derlin T. Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy. Eur J Nucl Med Mol Imaging. 2021;48(12):4077\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7817_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3857\/roj.2018.00290","volume":"36","author":"CB Dracham","year":"2018","unstructured":"Dracham CB, Shankar A, Madan R. Radiation induced secondary malignancies: a review article. Radiat Oncol J. 2018;36(2):85\u201394.","journal-title":"Radiat Oncol J"},{"issue":"6","key":"7817_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","volume":"24","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Herrmann K, Krause BJ, et al. Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(6):597\u2013610.","journal-title":"Lancet Oncol"},{"issue":"3","key":"7817_CR27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"7817_CR28","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","volume":"63","author":"C Schuchardt","year":"2022","unstructured":"Schuchardt C, Zhang J, Kulkarni HR, Chen X, Muller D, Baum RP. Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry. J Nucl Med. 2022;63(8):1199\u2013207.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07817-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07817-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07817-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:07:34Z","timestamp":1781636854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07817-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7817"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07817-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the ethical committee of Ludwig-Maximilians University (#25\u20130130), which waived the need for informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided informed consent for therapy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"RAW has received speaker honoraria from and reports advisory board work for Novartis\/AAA. RAB is Consultant for and has received speaker\u00b4s honoraria from Bayer Healthcare (Leverkusen, Germany), Novartis (N\u00fcrnberg, Germany), Terumo GmbH (Eschborn, Germany), and Eisai GmbH (Frankfurt, Germany) and has received travel expenses from Blue Earth Therapeutics (Oxford, UK).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}